gms | German Medical Science

Deutscher Rheumatologiekongress 2023

51. Kongress der Deutschen Gesellschaft für Rheumatologie (DGRh)
37. Jahrestagung der Deutschen Gesellschaft für Orthopädische Rheumatologie (DGORh)
33. Jahrestagung der Gesellschaft für Kinder- und Jugendrheumatologie (GKJR)

30.08. - 02.09.2023, Leipzig

Increased SLAMF7 expression on monocytes in rheumatoid arthritis

Meeting Abstract

  • Hannah Rebekka Spatzier - Universitätsklinikum Leipzig, Klinik und Poliklinik für Endokrinologie, Nephrologie, Rheumatologie, Leipzig
  • Laurin Braune - Universitätsklinikum Leipzig, Klinik und Poliklinik für Endokrinologie, Nephrologie, Rheumatologie, Leipzig
  • Anne-Marie Glimm - Universitätsklinikum Leipzig, Klinik und Poliklinik für Endokrinologie, Nephrologie, Rheumatologie, Leipzig
  • Olga Seifert - Universitätsklinikum Leipzig, Klinik und Poliklinik für Endokrinologie, Nephrologie, Rheumatologie, Leipzig
  • Marco Krasselt - Universitätsklinikum Leipzig, Klinik und Poliklinik für Endokrinologie, Nephrologie, Rheumatologie, Leipzig
  • Matthias Pierer - Universitätsklinikum Leipzig, Klinik und Poliklinik für Endokrinologie, Nephrologie, Rheumatologie, Leipzig
  • Ulf Wagner - Universitätsklinikum Leipzig, Klinik und Poliklinik für Endokrinologie, Nephrologie, Rheumatologie, Leipzig
  • Kathrin Rothe - Universitätsklinikum Leipzig, Klinik und Poliklinik für Endokrinologie, Nephrologie, Rheumatologie, Leipzig

Deutsche Gesellschaft für Rheumatologie. Deutsche Gesellschaft für Orthopädische Rheumatologie. Gesellschaft für Kinder- und Jugendrheumatologie. Deutscher Rheumatologiekongress 2023, 51. Kongress der Deutschen Gesellschaft für Rheumatologie (DGRh), 37. Jahrestagung der Deutschen Gesellschaft für Orthopädische Rheumatologie (DGORh), 33. Jahrestagung der Gesellschaft für Kinder- und Jugendrheumatologie (GKJR). Leipzig, 30.08.-02.09.2023. Düsseldorf: German Medical Science GMS Publishing House; 2023. DocET.05

doi: 10.3205/23dgrh025, urn:nbn:de:0183-23dgrh0251

Veröffentlicht: 30. August 2023

© 2023 Spatzier et al.
Dieser Artikel ist ein Open-Access-Artikel und steht unter den Lizenzbedingungen der Creative Commons Attribution 4.0 License (Namensnennung). Lizenz-Angaben siehe http://creativecommons.org/licenses/by/4.0/.


Gliederung

Text

Introduction: Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease of unknown etiology. Recurrent inflammation results in phenotypic alterations and modification of immune cell functions. SLAMF7 (CD319, CS-1, CRACC) is expressed on all hematopoietic cells and is known to have contrary effects on the regulation of immune cells [1]. On monocytes, it is reported that the SLAMF7 receptor plays an inhibitory role by suppressing proinflammatory immune responses [2]. Therefore, we are interested in the role of SLAMF7 expression on peripheral monocytes in relation to the dysfunctional immune regulation of RA.

Methods: Patients with diagnosed RA and healthy volunteers were recruited and clinical parameters, e.g. serum C-reactive protein (CRP) levels, rheumatoid factor (RF) IgM and anti-citrullinated protein antibodies (ACPAs) levels were assessed. Peripheral blood mononuclear cells (PBMCs) were isolated by density gradient centrifugation and SLAMF7 expression was analyzed by flow cytometry.

Results: Preliminary results show that frequency and SLAMF7 expression of RA monocytes (n=7) are reduced in comparison with healthy individuals (n=4). Further explorations show that this is the case for each subtype of monocytes, classical (CD14++ CD16-; mean RA 17.9% vs HD 28.8%), intermediate (CD14+ CD16+; mean RA 26.5% vs. HD 40.7%) and non-classical (CD14 low CD16+; mean RA 50.7% vs. HD 72.3%). Interestingly, we found a positive correlation between SLAMF7 expression and expression of CD16. In line with this result, classical monocytes express less SLAMF7 (MFI: mean RA 123 vs. HD 161), whereas non-classical monocytes show highest SLAMF7 expression (MFI: mean RA 286 vs. HD 395).

Conclusion: We are the first to show SLAMF7 expression on monocytes in relation to RA. In our study, we found that RA monocytes have reduced SLAMF7 expression and frequency in contrast to healthy individuals. Since SLAMF7 is known to have an inhibitory role in monocytes, our findings indicate an anti-inflammatory effect of SLAMF7 in the dysfunctional immune regulation of RA.

Disclosure: I declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.


References

1.
Kim JR, Horton NC, Mathew SO, Mathew PA. CS1 (SLAMF7) inhibits production of proinflammatory cytokines by activated monocytes. Inflamm Res. 2013 Aug;62(8):765-72. DOI: 10.1007/s00011-013-0632-1 Externer Link
2.
Wu Y, Wang Q, Li M, Lao J, Tang H, Ming S, Wu M, Gong S, Li L, Liu L, Huang X. SLAMF7 regulates the inflammatory response in macrophages during polymicrobial sepsis. J Clin Invest. 2023 Mar 15;133(6):e150224. DOI: 10.1172/JCI150224 Externer Link